Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (72)

2024

  1. Hepatic hemodynamic study: More than just HVPG measurement

    Gastroenterologia y Hepatologia

2023

  1. Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice

    Frontiers in Microbiology, Vol. 13

  2. An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting

    Advances in Therapy, Vol. 40, Núm. 7, pp. 3006-3020

  3. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding

    Gut, Vol. 72, Núm. 4, pp. 749-758

  4. Lack of Cyclin E1 in hepatocytes aggravates ethanol-induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver disease

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1869, Núm. 4

  5. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062

  6. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

  7. Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study

    Therapeutic Advances in Gastroenterology, Vol. 16

  8. Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD

    Liver International, Vol. 43, Núm. 9, pp. 1909-1919

2022

  1. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

    Cancers, Vol. 14, Núm. 1

  2. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  3. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  4. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease

    Journal of Hepatology, Vol. 76, Núm. 4, pp. 812-821

  5. Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study

    European Journal of Neurology, Vol. 29, Núm. 2, pp. 400-412

  6. Non-invasive tests for clinically significant portal hypertension after HCV cure

    Journal of Hepatology, Vol. 77, Núm. 6, pp. 1573-1585

2021

  1. A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt

    European journal of gastroenterology & hepatology, Vol. 33, Núm. 1S Suppl 1, pp. e587-e593

  2. An Experimental DUAL Model of Advanced Liver Damage

    Hepatology Communications, Vol. 5, Núm. 6, pp. 1051-1068

  3. Cardiac extracellular matrix hydrogel enriched with polyethylene glycol presents improved gelation time and increased on-target site retention of extracellular vesicles

    International Journal of Molecular Sciences, Vol. 22, Núm. 17

  4. Fat: Quality, or quantity? what matters most for the progression of metabolic associated fatty liver disease (mafld)

    Biomedicines, Vol. 9, Núm. 10

  5. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?

    World Journal of Gastroenterology, Vol. 27, Núm. 40, pp. 6737-6749